Role of endothelin-1 in hypertension

被引：62

作者：

Iglarz, M ^{[1
]}

Schiffrin, EL ^{[1
]}

机构：

[1] Clin Res Inst Montreal, Montreal, PQ H2W 1R7, Canada

来源：

CURRENT HYPERTENSION REPORTS | 2003年 / 5卷 / 02期

基金：

加拿大健康研究院;

关键词：

D O I：

10.1007/s11906-003-0071-4

中图分类号：

R6 [外科学];

学科分类号：

1002 ; 100210 ;

摘要：

Endothelin-1 (ET-1) was first characterized as a potent vasoconstrictor and is overexpressed in the vasculature in different models of hypertension, such as deoxycorticosterone acetate-salt rats, Dahl salt-sensitive rats, and stroke-prone spontaneously hypertensive rats. Moreover, patients with moderate to severe hypertension present increased vascular levels of prepro-ET-1 mRNA. In addition to their blood pressure-lowering effects, ET receptor antagonists are able to reduce vascular growth. Recent data suggest the involvement of an inflammatory response in the effects of ET-1, which contributes to vascular remodeling and endothelial dysfunction. Increasing evidence underscores the potential therapeutic benefit of ET receptor antagonists in different hypertension-related complications, not only in essential hypertension, but also in patients with type 2 diabetes.

引用

页码：144 / 148

页数：5